Peter E. Westerweel

St. Antonius Ziekenhuis
Nieuwegein, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Increased Mast Cell Numbers in Bone Marrow of Patients with Myeloproliferative Neoplasms (MPN) and Pruritus.

Increased Mast Cell Numbers in Bone Marrow of Patients with Myeloproliferative Neoplasms (MPN) and Pruritus.

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: June 26, 2026

Increased Mast Cell Numbers in Bone Marrow of Patients with Myeloproliferative Neoplasms and Pruritus

Increased Mast Cell Numbers in Bone Marrow of Patients with Myeloproliferative Neoplasms and Pruritus

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: June 26, 2026

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Journal: Blood neoplasia

Published: December 02, 2025

Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma.

Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma.

Journal: American journal of hematology

Published: November 01, 2025

Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study.

Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study.

Journal: Haematologica

Published: June 26, 2025

The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial.

The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial.

Journal: Frontiers in oncology

Published: June 11, 2025

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.

Journal: The New England journal of medicine

Published: March 31, 2025

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Journal: Leukemia

Published: March 04, 2025

The 'Stop TPO-RA in ITP Patients' study: Clinical and immune modulatory effects of romiplostim tapering.

The 'Stop TPO-RA in ITP Patients' study: Clinical and immune modulatory effects of romiplostim tapering.

Journal: British journal of haematology

Published: January 16, 2025

Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases.

Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases.

Journal: Annals of hematology

Published: November 12, 2024

Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients.

Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients.

Journal: European journal of haematology

Published: August 25, 2024

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.

Journal: Annals of hematology

Published: July 23, 2024

Showing 1-12 of 95

Last Updated: 09/26/2026